One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

CNBC's Angelica Peebles talks to Structure Therapeutics CEO Ray Stevens about the obesity landscape and why there's still ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

BMI has long been falling out of favor. When the American Medical Association urged downgrading BMI in 2023, it blamed its ...

Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...

The FDA has designed five different types of labels, each presenting the same information but with different specifications based on the size of the packaging.

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...

An international group of experts proposes two new categories of disease: preclinical and clinical obesity and the FDA ...

It’s one thing for the scientific community to propose a fundamental change to the way obesity is defined and diagnosed. But ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.